Resistance to proteasome inhibitors in cancer : molecular mechanisms and strategies to overcome resistance /

The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases,...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Autor kompanije: SpringerLink (Online service)
Daljnji autori: Dou, Q. Ping
Format: e-knjiga
Jezik:English
Izdano: Cham Springer International Publishing 2014.
Serija:Resistance to Targeted Anti-Cancer Therapeutics
Teme:
Online pristup:Click here to view the full text content
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
Opis
Sažetak:The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume. This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.
Opis:1 online resource (XI, 390 pages) 55 illustration, 51 illustration in colour.
ISBN:9783319067520
ISSN:2196-5501